Analyst Price Targets — VYNE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 14, 2024 7:58 am | Joseph Pantginis | H.C. Wainwright | $5.75 | $2.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE) |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for VYNE

VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 121,535 shares, a decrease of 35.7% from the March 15th total of 188,899 shares. Based on an average daily trading volume, of 214,716

VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Volatility and Risk VYNE Therapeutics has a

VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 212,702 shares, a drop of 61.3% from the February 12th total of 549,047 shares. Based on an average daily trading volume, of 435,988 shares, the short-interest
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VYNE.
U.S. House Trading
No House trades found for VYNE.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
